Previous and current treatments of patients diagnosed with psoriasis with pPsA, axPsA and patients not diagnosed with PsA
| Patient group | |||||
| Patient characteristic | All patients seen at rheumatology (N=100) | pPsA (N=5) | axPsA (N=14) | No PsA (N=81) | P value* |
| NSAIDs use, current—n (%) | 42 (42.0) | 3 (60.0) | 8 (57.1) | 31 (38.3) | 0.185 |
| Analgesics (non-opioid) | 10 (10.0) | 0 | 2 (14.3) | 8 (9.9) | 0.620 |
| Analgesics (opioid) | 5 (5.0) | 0 | 2 (14.3) | 3 (3.7) | 0.102 |
| Systemic psoriasis therapy—n (%) | |||||
| Methotrexate | 11 (11.0) | 0 | 2 (14.3) | 9 (11.1) | 0.732 |
| Systemic retinoids | 2 (2.0) | 0 | 1 (7.1) | 1 (1.2) | 0.155 |
| Phosphodiesterase inhibitor | 1 (1.0) | 0 | 1 (7.1) | 0 | 0.016 |
| Systemic glucocorticoids | 1 (1.0) | 0 | 1 (7.1) | 0 | 0.016 |
| Other therapies | 3 (3.0) | 1 (20.0) | 0 | 2 (2.5) | 0.552 |
| Topical psoriasis therapy—n (%) | |||||
| Topical steroids | 78 (78.0) | 5 (100.0) | 12 (85.7) | 61 (75.3) | 0.394 |
| Vitamin D analogues | 52 (52.0) | 1 (20.0) | 4 (28.6) | 47 (58.0) | 0.041 |
| Topical retinoids | 1 (1.0) | 0 | 0 | 1 (1.2) | 0.676 |
| Topical calcineurin inhibitors | 1 (1.0) | 0 | 0 | 1 (1.2) | 0.676 |
| UVB therapy | 1 (1.0) | 0 | 0 | 1 (1.2) | 0.676 |
*Statistically significant differences between the axPsA and noPsA groups of patients were determined by using Mann–Whitney U test for continuous data and χ² test for categorical data
axPsA, axial psoriatic arthritis; N, number; NSAIDs, non-steroidal anti-Inflammatory drugs; pPsA, peripheral psoriatic arthritis; UVB, ultraviolet B.